Profil
Kathryn M.
McNeil worked as Head-Investor & Media Relations at Chelsea Therapeutics International Ltd. from 2009 to 2012.
She was also VP-Investor Relations & Public Relations at Novelos Therapeutics, Inc. from 2013 to 2014, and VP-Investor Relations & Corporate Communications at Cellectar Biosciences, Inc. from 2013 to 2015.
In 2017, she worked as Head-Communication & Investor Relations at Invitae Corp.
Ms. McNeil obtained an undergraduate degree from Wesleyan University.
Tidigare kända positioner av Kathryn M. McNeil
| Företag | Position | Slut |
|---|---|---|
| INVITAE CORPORATION | Offentlig kommunikationskontakt | 2018-04-01 |
| CELLECTAR BIOSCIENCES, INC. | Investor Relations Kontakt | 2015-07-28 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and provides pharmaceutical drugs | Investor Relations Kontakt | 2014-02-12 |
| CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Investor Relations Kontakt | - |
Kathryn M. McNeils utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
Chelsea Therapeutics International Ltd.
Chelsea Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company developing and commercializing therapeutics for a variety of human diseases | Health Technology |
Invitae Corp.
Invitae Corp. Medical/Nursing ServicesHealth Services Provides genetic testing services for patients | Health Services |
Wesleyan University
Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and provides pharmaceutical drugs | Health Technology |
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer | Health Technology |
















